M&A

AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug

Published on 6/22/2026

#ABBV#biotech#acquisition#atopicDermatitis
AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug

AI Summary

Summarized by AI from the source below

AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.

Share:
Source: Read original article (opens in new tab)

Get the free market brief

Top stories and analysis, summarized. No spam, unsubscribe anytime.

Related News

EasyJet (EZJ) agrees to Β£5.7bn takeover by Apollo
M&A

EasyJet (EZJ) agrees to Β£5.7bn takeover by Apollo

Aug 6

Liontrust Increases Everplay Group Stake to 6.5%
M&A

Liontrust Increases Everplay Group Stake to 6.5%

Aug 5

David Ellison on Paramount-Warner Antitrust Suit Updates
M&A

David Ellison on Paramount-Warner Antitrust Suit Updates

Aug 5

GM (GM) and SAIC Extend Joint Venture Partnership for 20 Years
M&A

GM (GM) and SAIC Extend Joint Venture Partnership for 20 Years

Aug 5